Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
暂无分享,去创建一个
K. Harrington | N. Senzer | K. Delman | I. Puzanov | M. Milhem | R. Coffin | H. Kaufman | M. Middleton | F. Collichio | S. Agarwala | J. Chesney | R. Andtbacka | T. Amatruda | L. Spitler | Ai Li | M. Shilkrut